I don't expect a buyout, but I do fully expect that Rainbow Coral Corp, who runs Rainbow Biosciences (RBBC), will provide ample cash to help Amarantus move out of the preclinical stage and into phase 1 clinical trials for the treatment of Parkinson's disease. I also hope that AMBS will secure funding to move along with phase 1 trials for treatment of Traumatic Brain Injury(TBI). The company's lead program MANF has the potential to treat both these diseases by addressing cell death. Now if they do not get funding, this stock and company could be worthless. But if they do get funding, and at least move forward with several phase 1 trials this stock and company could become very valuable. A very high risk/high reward stock, and only risk what you can afford to lose.